Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on April 23, 2019, reporting events occurring on April 17, 2019. The filing addresses corporate governance changes, specifically the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size to eight members.
- New Appointment: Dr. Bahija Jallal was appointed as a Class III independent director, effective April 17, 2019.
- Committee Assignments: Dr. Jallal was appointed to the Audit Committee (replacing Samir Kaul) and the Nominating and Corporate Governance Committee.
- Term: Her term expires at the 2021 Annual Meeting of Stockholders.
Compensation and Management Commentary
Dr. Jallal will receive standard non-employee director fees. Additionally, she was granted equity awards on the date of appointment:
- Stock Option Award: Value of $215,000 with an exercise price of $72.71 per share.
- Restricted Stock Unit (RSU) Award: Value of $215,000.
- Vesting Schedule: Both awards vest in three equal installments (one-third) on each of the first three anniversaries of her appointment, contingent on continued service.
Management cites Dr. Jallal's extensive biopharmaceutical experience, including her role as CEO of Immunocore Limited and former Executive Vice President at AstraZeneca, as the rationale for her qualification.
Investor Verification Checklist
- Verify Dr. Jallal's current roles and potential conflicts of interest with Immunocore Limited and Anthem, Inc.
- Confirm the impact of the Audit Committee change on the company's financial oversight structure.
- Review the full text of the standard indemnification agreement referenced in the filing (Exhibit 10.8 of Form S-1/A).
- Monitor future filings for the vesting status of the $430,000 total equity grant.